Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

RVNC INVESTOR ALERT: Investigation of Revance Therapeutics, Inc. Announced by Glancy Prongay & Murray LLP

RVNC

Glancy Prongay & Murray LLP announces that it is investigating potential claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) concerning the Company’s and its officers’ possible violations of federal securities laws.

The investigation focuses on the allegedly misleading statements found in the Company’s public statements and SEC filings which failed to disclose, among other things, that: (i) Revance had not commenced a Phase 3 clinical trial of RT0001—its lead product under development for the treatment of wrinkles around the eyes—in the first quarter of 2014; and (ii) Revance did not have the quality or quantity of RT0001 on hand sufficient to complete a successful Phase 3 clinical trial. When the true details entered the market, the Company’s share price declined sharply and investors suffered damages.

If you have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today